The company said second-quarter sales from continuing operations of $2.81 billion rose 4% on a reported basis and 1% on an operational basis. It said the results were in line with its previously issued outlook.

1. 01

   The company said second-quarter sales from continuing operations of $2.81 billion rose 4% on a reported basis and 1% on an operational basis. It said the results were in line with its previously issued outlook.

2. 02

   Baxter reported second-quarter U.S. GAAP diluted earnings per share from continuing operations of $0.24 (net income of $122 million) and adjusted diluted EPS of $0.59, up 28% from $0.46 a year earlier.

3. 03

   The company reported gross margin of 35.3% for Q2 2025, 3.0 pts lower than 38.3% in the same period a year earlier. It said GAAP operating income was $191 million and adjusted operating income was $423 million.

4. 04

   The company said it expects continuing operations sales growth for 2025 of 6% to 7% on a reported basis and 3% to 4% on an operational basis. It also expects adjusted diluted EPS of $2.42 to $2.52. For Q3, it expects adjusted diluted EPS of $0.58 to $0.62.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.